Methobion (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This reduces the synthesis of nucleotides needed for DNA and RNA, thereby limiting the proliferation of rapidly dividing cells and modulating immune responses.

The specific dose of Methobion is determined by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and treatment goals. Dosage regimens are individualized and not standardized across all patients.

Methobion is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To request Methobion, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methobion (methotrexate) shares a mechanism with other folate antagonists but is distinguished by its broad therapeutic range, including both oncologic and autoimmune indications. Compared with newer agents, it is generally less expensive but requires careful monitoring for toxicity.

Methobion should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability.

Methobion is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intrathecal routes, depending on the indication and clinical protocol established by the treating physician.

The most serious risks include bone marrow suppression leading to severe pancytopenia, hepatotoxicity that may progress to fibrosis, pulmonary toxicity such as interstitial pneumonitis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome.

Methobion should not be used in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic or renal impairment, and those with active infections that could be worsened by immunosuppression.